Literature DB >> 26991151

Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.

Jessica C Young1, Til Stürmer1, Jennifer L Lund1, Michele Jonsson Funk1.   

Abstract

PURPOSE: Few studies have evaluated the degree to which prescription drug initiators are correctly identified using claims data. We examine the prevalence and predictors of recent statin possession in statin initiators identified using claims data.
METHODS: Among Medicare Current Beneficiary Survey (MCBS) respondents, we used Medicare Part D claims from 2006 to 2011 to identify statin initiators using a 12-month baseline period of no prior statin claims. Using MCBS interview data, we identified those with self-reported statins obtained during the baseline period. We used log-binomial regression to estimate adjusted prevalence ratios (adjPR) and 95% confidence intervals (CI) for predictors of recent statin possession.
RESULTS: Among 766 statin initiators identified in prescription claims, 155 (20%) reported recent statin possession during baseline. Beneficiaries with no Part D claims in the past 30 days (adjPR = 1.49, 95%CI: 1.13, 1.96), those with no inpatient, outpatient or physician visits in the past 30 days (adjPR = 1.50, 95%CI: 1.11, 2.03), those with a brand name statin index claim (adjPR = 1.55, 95%CI: 1.19, 2.02), and those with an index claim in January or February (adjPR = 1.50, 95%CI: 1.00, 2.26) had an increased probability of recent statin possession.
CONCLUSIONS: In a cohort of statin initiators identified using prescription claims, 20% had evidence of statin possession during the baseline period. Pharmacoepidemiologic new user studies may benefit from including sensitivity analyses within subgroups less likely to include prevalent users to assess the robustness of key findings to misidentification of the time of treatment initiation.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Medicare Current Beneficiary Survey; administrative claims; new user design; pharmacoepidemiology; statins

Mesh:

Substances:

Year:  2016        PMID: 26991151      PMCID: PMC5279925          DOI: 10.1002/pds.3991

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  13 in total

1.  How the doughnut hole affects prescription fulfillment decisions involving cardiovascular medications for Medicare Part D enrollees.

Authors:  John W Hales; Stephen George
Journal:  Manag Care       Date:  2010-12

2.  Out-of-plan medication in Medicare Part D.

Authors:  Pamela N Roberto; Bruce Stuart
Journal:  Am J Manag Care       Date:  2014-09       Impact factor: 2.229

3.  Cardiovascular and mortality risks in older Medicare patients treated with varenicline or bupropion for smoking cessation: an observational cohort study.

Authors:  David J Graham; Kunthel By; Stephen McKean; Andrew Mosholder; Cynthia Kornegay; Judith A Racoosin; Jessica Young; Mark Levenson; Thomas E MaCurdy; Chris Worrall; Jeffrey A Kelman
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-07-05       Impact factor: 2.890

4.  Metformin and cancer: mounting evidence against an association.

Authors:  Samy Suissa; Laurent Azoulay
Journal:  Diabetes Care       Date:  2014-07       Impact factor: 19.112

5.  Analgesic use, blood dyscrasias, and case-control pharmacoepidemiology. A critique of the International Agranulocytosis and Aplastic Anemia Study.

Authors:  M S Kramer; D A Lane; T A Hutchinson
Journal:  J Chronic Dis       Date:  1987

6.  The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.

Authors:  Jennifer L Lund; David B Richardson; Til Stürmer
Journal:  Curr Epidemiol Rep       Date:  2015-09-30

7.  Acute kidney injury in statin initiators.

Authors:  J Bradley Layton; M Alan Brookhart; Michele Jonsson Funk; Ross J Simpson; Virginia Pate; Til Stürmer; Abhijit V Kshirsagar
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-08-20       Impact factor: 2.890

8.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

9.  Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device.

Authors:  Katia Bruxvoort; Charles Festo; Matthew Cairns; Admirabilis Kalolella; Frank Mayaya; S Patrick Kachur; David Schellenberg; Catherine Goodman
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

10.  Reporting of drug expenditures in the MCBS.

Authors:  John A Poisal
Journal:  Health Care Financ Rev       Date:  2003
View more
  2 in total

1.  Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.

Authors:  Akinyemi Oni-Orisan; Thomas J Hoffmann; Dilrini Ranatunga; Marisa W Medina; Eric Jorgenson; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren; Neil Risch
Journal:  Circ Genom Precis Med       Date:  2018-09

2.  Racial differences in statin adherence following hospital discharge for ischemic stroke.

Authors:  Karen C Albright; Hong Zhao; Justin Blackburn; Nita A Limdi; T Mark Beasley; George Howard; Vera Bittner; Virginia J Howard; Paul Muntner
Journal:  Neurology       Date:  2017-04-12       Impact factor: 9.910

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.